m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02002)
Name
6-Benzyloxy-9H-purin-2-ylamine
Synonyms
6-O-Benzylguanine; 19916-73-5; 6-(Benzyloxy)-7H-purin-2-amine; 2-amino-6-benzyloxypurine; 6-(benzyloxy)-9H-purin-2-amine; 2-Amino-6-(benzyloxy)purine; O(6)-Bgua; 6-(Benzyloxy)guanine; 6-Benzyloxyguanine; 6-Benzyloxy guanine; 6-(Phenylmethoxy)-1H-purin-2-amine; 2-Amino-6-(phenylmethoxy)-9H-purine; O6-BG; UNII-01KC87F8FE; 1H-Purin-2-amine, 6-(phenylmethoxy)-; 6-BENZYLGUANINE; Purine, 2-amino-6-(benzyloxy)-; NSC 637037; CHEMBL407874; 01KC87F8FE; 6-benzyloxy-7H-purin-2-amine
    Click to Show/Hide
Status
Investigative
Structure
Formula
C12H11N5O
InChI
1S/C12H11N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H3,13,14,15,16,17)
InChIKey
KRWMERLEINMZFT-UHFFFAOYSA-N
PubChem CID
4578
TTD Drug ID
D0B5BG
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
O-6-methylguanine-DNA-alkyltransferase (MGMT)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary O-6-methylguanine-DNA-alkyltransferase (MGMT) is a therapeutic target for 6-Benzyloxy-9H-purin-2-ylamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-Benzyloxy-9H-purin-2-ylamine through regulating the expression of O-6-methylguanine-DNA-alkyltransferase (MGMT). [1], [2]
References
Ref 1 METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m(6)A Dependent Manner. Front Oncol. 2021 Jul 15;11:702983. doi: 10.3389/fonc.2021.702983. eCollection 2021.
Ref 2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.